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Adenosine deaminase 2 (ADA2) deficiency is an auto-inflammatory disease due to
mutations in cat eye syndrome chromosome region candidate 1 (CECR1) gene,
currently named ADA2. The disease has a wide clinical spectrum encompassing
early-onset vasculopathy (targeting skin, gut and central nervous system), recurrent fever,
immunodeficiency and bone marrow dysfunction. Different therapeutic options have
been proposed in literature, but only steroids and anti-cytokine monoclonal antibodies
(such as tumor necrosis factor inhibitor) proved to be effective. If a suitable donor is
available, hematopoietic stem cell transplantation (HSCT) could be curative. Here we
describe a case of ADA2 deficiency in a 4-year-old Caucasian girl. The patient was initially
classified as autoimmune neutropenia and then she evolved toward an autoimmune
lymphoproliferative syndrome (ALPS)-like phenotype. The diagnosis of ALPS became
uncertain due to atypical clinical features and normal FAS-induced apoptosis test.
She was treated with G-CSF first and subsequently with immunosuppressive drugs
without improvement. Only HSCT from a 9/10 HLA-matched unrelated donor, following
myeloablative conditioning, completely solved the clinical signs related to ADA2
deficiency. Early diagnosis in cases presenting with hematological manifestations, rather
than classical vasculopathy, allows the patients to promptly undergo HSCT and avoid
more severe evolution. Finally, in similar cases highly suspicious for genetic disease, it is
desirable to obtain molecular diagnosis before performing HSCT, since it can influence
the transplant procedure. However, if HSCT has to be performed without delay for clinical
indication, related donors should be excluded to avoid the risk of relapse or partial benefit
due to a hereditary genetic defect.
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INTRODUCTION
Deficiency of adenosine deaminase 2 (DADA2) is a genetic auto-
inflammatory disease caused by autosomal recessive mutations
in adenosine deaminase 2 (ADA2) gene, mapped on chromosome
22q11 (1). Adenosine deaminase 2 (ADA2) is an enzyme secreted
in the plasma by myeloid cells that catalyzes the conversion
of adenosine to inosine (2). The pathomechanism of DADA2
remains unclear, but immunomodulatory function of ADA2 is
crucial. Indeed, in vitro studies suggest that ADA2 works as an
autocrine factor activating cells of the immune system (3). Thus,
deficiency of ADA2 results in multiple immune abnormalities,
such as increased pro-inflammatory M1 macrophages (as
opposed to anti-inflammatoryM2macrophages), upregulation of
genes associated with neutrophil activation, increased secretion
of pro-inflammatory cytokines including TNF and interleukin-
1b (IL-1b) and endothelial damage (4, 5).
DADA2 was described for the first time in 2014 by
two independent studies (4, 6). The predominant clinical
presentation includes recurrent fever, early-onset vasculopathy
involving skin, gut and central nervous system (1, 7, 8). Blood
tests usually show elevation of acute phase reactants (erythrocyte
sedimentation rate and C-reactive protein) (1). Recent evidences
suggest a broader clinical spectrum encompassing also features of
autoimmunity, immunodeficiency and bonemarrow dysfunction
(1, 8–14). The diagnosis of DADA2 is based on the measurement
of plasma ADA2 enzymatic activity and on the identification of
biallelic mutations in ADA2.
Splenomegaly or hepatosplenomegaly are frequently reported
in patients with DADA2 deficiency (1, 4, 11, 15, 16) as
well as cytopenia (1, 4, 11, 17). Nevertheless, their presence
in addition to clinical and biological features defining an
Autoimmune Lymphoproliferative Syndrome (ALPS)-like
phenotype is less common. Only two cases of DADA2 presenting
with clinical features resembling ALPS have been recently
described (17, 18). Another patient experienced hemophagocytic
lymphohistocytosis on a background of ALPS-likemanifestations
(19).
We describe a case of ADA2 deficiency presenting as
ALPS-like disease, unresponsive to immunosuppressive therapy,
successfully treated with allogeneic hematopoietic stem cell
transplantation (HSCT).
CASE PRESENTATION
A 4-year old Caucasian female child was referred to our Center
for diagnostic assessment of severe neutropenia lasting for
6 months that was not responsive to the administration of
granulocyte-colony stimulating factor (G-CSF) up to amaximum
dose of 20 mcg/kg daily.
The patient was born after a full-term gestation, from non-
consanguineous parents. The birth weight was 3,600 g. Familial
medical history was unremarkable. Parents reported recurrent
infections of upper respiratory tract and stomatitis during the
first years of life, before the occurrence of severe neutropenia.
Physical examination was normal, except for the presence
of splenomegaly (long axis 11.5 cm at ultrasound scan),
whereas blood count revealed profound neutropenia (absolute
neutrophil count, ANC, 0.02 × 109/L) without anemia and
thrombocytopenia. Bone marrow examination showed the
presence of rare myeloid precursors with normal representation
of the erythroid and megakaryocyte lineages. The clonogenic
study of bone marrow progenitors in vitro showed a normal
growth of erythroid cells whereas the growth of myeloid cells
was below the normal range: CFU-E/BFU-E 37 (normal range
27–81/2 × 104); CFU-GEMM 1 (normal range 0–10/2 × 104);
CFU-GM 30 (normal range 33–100/2 × 104). Interestingly the
patient bone marrow plasma markedly inhibited the growth of
progenitor cells obtained from healthy voluntary bone marrow
donors: CFU-E/BFU-E/(2 × 105) from 88 (controls) to 4
(controls + patient plasma), CFU-GEMM/(2 × 105) from 17
to 9. An extensive diagnostic work-up excluded other potential
causes of neutropenia such as Kostmann disease, Shwachman-
Diamond syndrome, Fanconi anemia and paroxysmal nocturnal
hemoglobinuria. Finally, a misdiagnosed form of autoimmune
neutropenia was hypothesized. Indeed, anti-neutrophil IgG were
171.1 mg/dL (normal value< 33.5 mg/dL), IgM were 24.9 mg/dL
(normal value < 32.2 mg/dL). Hence, the patient underwent a 4-
week trial with prednisone at 2.5 mg/kg/day that led to complete
remission of neutropenia (ANC 3.360 × 109/L). Prednisone
was slowly tapered. Nevertheless, fever occurred at every
attempt of reducing the dose of prednisone below 1 mg/kg/day.
Given the significant side effects after 3 months of steroid
therapy, introduction of steroid-sparing agents (cyclosporine
first and mycophenolate mofetil later) was attempted. However,
neutropenia did not improve and the patient remained steroid
dependent.
After 4 months, she experienced a single episode of livedo
reticularis at the lower limbs. The histological examination
showed a livedoid thrombotic vasculopathy. Moreover, the
patient was hospitalized eight times due to episodes of fever,
abdominal pain and neutropenia with elevated inflammation
markers. Abdominal CT scan, esophagogastroduodenoscopy
(EGDS) and colonoscopy showed no abnormalities, as well as
gastrointestinal biopsies.
The patient was assessed also for ALPS (Table 1) (20) because
of autoimmune neutropenia and splenomegaly: she displayed
increased double negative T-lymphocytes in the peripheral blood
(2.5%, normal value <1.7% of total lymphocytes), IL-18 (1.125
pg/ml, normal value 36–258 pg/ml), IL-10 (7.2 pg/ml, normal
value < 1 pg/ml). However, vitamin B12 levels where only
mildly elevated as compared to patients with classical ALPS
(775 pg/mL, normal value 191–663) (21); similarly, FAS-induced
apoptosis test was normal (survivor T-lymphocytes after FAS
antigenic stimulation 42%) (22). Sirolimus was started (23,
24) and withdrawn after 2 months, due to the occurrence of
fever and abdominal pain. Prednisone was continued alone. No
mutations were found in ALPS-disease causative genes (FAS,
FASL, CAS10). The control of clonogenic tests 7 months after
starting immunosuppression showed a good growth of CFU-
E/BFU-E (120/2 × 104) and CFU-GEMM (52/2 × 104); the
growth of bone marrow progenitor cells derived from healthy
donors was no more inhibited by the patient’s bone marrow
plasma.
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TABLE 1 | Diagnostic criteria for ALPS defined by 2009 NIH consensus (20).
Required
1. Chronic (6 months), nonmalignant, noninfectious lymphadenopathy or
splenomegaly or both
2. Elevated CD3 + TCRαβ + CD4-CD8- DNT cells (1.5% of total lymphocytes or




1. Defective lymphocyte apoptosis (in 2 separate assays)
2. Somatic or germline pathogenic mutation in FAS, FASL, or CASP10
Secondary
1. Elevated plasma sFASL levels (>200 pg/mL) OR elevated plasma IL-10 levels
(>20 pg/mL) OR elevated serum or plasma vitamin B12 levels (>1,500 ng/L) OR
elevated plasma IL-18 levels (>500 pg/mL)
2. Typical immunohistological findings as reviewed by an experienced
hematopathologist
3. Autoimmune cytopenias (hemolytic anemia, thrombocytopenia, or
neutropenia) AND elevated immunoglobulin G levels (polyclonal
hypergammaglobulinemia)
4. Family history of a nonmalignant/noninfectious lymphoproliferation with or
without autoimmunity
Definitive diagnosis: required criteria plus one primary accessory criterion.
Probable diagnosis: required criteria plus one secondary criterion.
CASP10 caspase 10, DNT double-negative T cell, FASL Fas-ligand, Ig immunoglobulin,
IL interleukin, NIH National Institutes of Health, sFasL soluble Fas ligand.
Considering the persistence of neutropenia despite the
administration of G-CSF and immunosuppressive therapy, the
patient was candidate to allogeneic HSCT. During pre-transplant
workup, brain magnetic resonance (MRI) revealed a 5-mm signal
alteration in the right cortical-subcortical frontal basal region
consistent with a petechial spot.
HSCT was performed at 5 years and 4 months of age.
The patient underwent a myeloablative conditioning with
busulfan, thiotepa, fludarabine and rituximab (Table 2). Graft-
vs.-host disease (GVHD) prophylaxis consisted of anti-thymocite
globulin, short methotrexate, cyclosporine (from day 0 to day
+28) than replaced by tacrolimus (from day +29). Neutrophil
engraftment occurred on day +26, and platelet engraftment
occurred on day +34. Complete donor chimerism was detected
on day +33. Main complications after HSCT were gut and
skin grade II acute GVHD requiring additional therapy with
prednisone at 2 mg/kg/day, tapered slowly due to frequent
relapses. Further complications were: CMV reactivation (on day
+ 31) treated successfully with valganciclovir and osteonecrosis
of the knees (on day + 138), treated with vitamin D, calcium,
bisphosphonates, physio-kinesiotherapy and hyperbaric oxygen
therapy.
Considering the atypical clinical evolution, the inadequate
response to therapy and the absence of mutations, the diagnosis
of ALPS was questioned. We performed molecular analysis by
Haloplex target system platform (Illumina) on the patient’s buccal
swab obtained after HSCT. The patient resulted compound
heterozygous for two novel mutations in ADA2 gene. The variant
located at exon 9 determines an amino acidic substitution (c.1367
A>G, p.Y456C) and the variant located in exon 8 introduces
a premature stop codon causing the synthesis of a truncated
TABLE 2 | Conditioning regimen.
Drug Dosage
Fludarabine 3 × 50 mg/m2/day
Thiotepa 2 × 5 mg/kg/day
Busulfan 16 × 0.8 mg/kg (every 6 h)
ATG Genzyme 3 × 4 mg/kg/day
Rituximab 1 × 375 mg/m2/day
protein (c.1196. G>A, p.W399∗). Both parents were healthy
heterozygous carriers. These new mutations are reported as
detrimental for the protein according to different prediction tools
(e.g., PROVEAN, PolyPhen).
The high-resolution crystal structure of the homodimeric
wild type protein was previously determined (PDB ID 3LGD,
corresponding to UniProt Q9NZK5 amino acid residues 29-
510, Zavialov et al.,http://dx.doi.org/10.1074/jbc.M109.083527).
To address the effects of the two mutations, we performed a
structural and energetic analysis of the enzyme. The p.Y456C
mutation affects a hydrophobic pocket of ADA2 (Figure 1A).
Of note, this is a novel mutation but the p.Y453C mutation,
which affects the same hydrophobic pocket, is one of the most
common found in patients with DADA2 (1). The p.Y456C
mutation carried by our patient heavily destabilizes the ADA2
structure (11G= 4.53± 0.12 kcal/mol from n= 5 independent
simulations) as calculated using the program FoldX (25). The
p.W399∗ mutation instead leads to a truncation of the protein C-
terminus, removing key residues required for the correct folding
of the active site, and resulting in a solvent-exposed catalytic
Zn2+ ion (Figure 1B). Thus, both mutations are predicted to
dramatically reduce the enzymatic activity of ADA2 through
structural destabilization of the protein.
Pre-HSCT plasma of the patient was not available but we
could assess ADA2 activity in the parents, which resulted lower
than healthy controls as expected in carriers, supporting the
deleterious effect of the mutations on the protein function.
Moreover, patient’s ADA2 plasma activity after HSCT was
normal, in the absence of clinical manifestations of the disease
and in the presence of full donor chimerism (Table 3). These
results strongly suggest DADA2 as cause of the hematological
manifestations of the patient.
The patient gradually recovered from HSCT complications
and immunosuppressive therapy was withdrawn. She is now alive
and well 28 months after HSCT enjoying a normal life.
DISCUSSION
Clinical phenotype and age at onset of DADA2 vary widely
without clear correlation to ADA2 genotype (8).
Although not described initially, hematological disorders
appear to be an emergent clinical manifestation of DADA2.
A various degree of hematological dysfunction affects
approximately 43% of patients, in the absence of evident
vasculitis (14). Anemia, including pure red cell aplasia, and
lymphopenia are the most frequent findings, while neutropenia
is a rare clinical manifestation (1, 13, 14).
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FIGURE 1 | (A) Location of the p.Y456C mutation. The Y456 residue is located in an α-helical segment and inserted between hydrophobic residues. (B) Structural
abnormality of the ADA2 protein generated by the p.W399* mutation. In yellow, the portion of the protein that is lacking due to the stop codon introduced by the
mutation. Figures generated with Pymol (http://www.pymol.org).
TABLE 3 | Plasma ADA2 activity in the index family.
Sample Age (year) Plasma ADA2
activity* (mU/mL)
Patient post-HSCT 7 21.4
Mother 32 4.2
Father 36 4.9
Reference values for plasma ADA2 activity* (mU/mL),
mean ± SD (range)
ADA2 deficient (n = 36) 0.4 ± 0.5 (0.02 – 1.9)
ADA2 carriers (n = 25) 5.5 ± 1.7 (2.9 – 8.8)
Controls (N = 23 + pooled human plasma) 13.8 ± 5.1 (4.8 – 27.2)
*obtained using the HPLC assay described in Zhou et al. (4).
Initially, our patient was classified as an ALPS-like based
on autoimmune neutropenia, splenomegaly and positive
biomarkers. Subsequently, the diagnosis of ALPS became less
certain because of the lack of response to immunosuppressive
drugs, atypical clinical features (livedo reticularis and recurrent
severe abdominal pain), normal FAS-induced apoptosis test,
and lack of mutations of ALPS-related genes. Only widening
the genetic evaluation after HSCT in the index case and in the
parents, DADA2 was diagnosed. Of note, clinical presentation of
DADA2 as ALPS-like disease have been reported in two patients
(17, 18) who were successfully treated with HSCT and anti-TNF
medications respectively.
Of note, during the active phase of the disease, the
patient’s bone marrow plasma markedly inhibited the growth of
progenitor cells obtained fromhealthy bonemarrow donors. This
finding and the reversion of inhibition after administration of
steroids, suggests the presence of pro-inflammatory mediators
inhibiting the growth of bone marrow progenitor cells, as
observed in the setting of acquired aplastic anemia, where plasma
pro-inflammatory cytokines block the differentiation of bone
marrow progenitor cells (26). This further supports the possible
benefit derived by the administration of TNF-inhibitors in ADA2
patients before transplant, in order to reduce the inflammatory
burden also in the bone marrow niches (14). Current literature
suggests different therapeutic options for DADA2: the choice
between medical therapy and HSCT depends on predominant
symptoms and severity of the clinical phenotype. Being an
inflammatory condition, high doses of steroids are usually useful
to control the disease, although a steroid-dependence often
occurs (5), as in the case herein described. If inflammatory
symptoms and vasculitis are predominant, anti–tumor necrosis
factor agents are usually beneficial (6, 7, 11, 14). HSCT is a
potential definitive treatment, since it provides ADA2 producing
monocytes, which are able to restore ADA2 plasma activity and
control the disease manifestations (15, 17, 19, 27). Moreover,
as recently reported by Hashem et al. (28), bone marrow
dysfunction and immunodeficiency are the most frequent
indications leading to transplant.
Our experience suggests that ADA2 deficiency should
be considered as differential diagnosis in cases of severe
autoimmune neutropenia evolving to ALPS-like disease not
responsive to standard immunosuppressive approaches. Early
diagnosis based on these manifestations could allow prompt
therapeutic intervention anticipating the onset of vasculopathy
and related severe complications.
Importantly, clinicians should aim at obtaining the molecular
diagnosis of putative genetic diseases before transplant, since it
could influence the management of patients candidate to HSCT.
This particularly applies in ADA2 deficiency, considering the
high risk of complications due to the persisting inflammation
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and the impaired endothelial integrity (17, 19, 29). In this
light, anti-TNF therapy administered before the conditioning
can reduce vascular inflammation (14). With the same aim,
conditioning should be tailored, for example replacing Busulfan
with Treosulfan or other agents displaying lower endothelial
toxicity. Another strategy can foresee prophylactic Defibrotide to
reduce the risk of sinusoidal obstruction syndrome. In addition,
the selection of the donor can favor unrelated donor avoiding
carrier familial donors who might display partial reduction
of ADA2 activity. This partial defect can be amplified in the
presence of mixed chimerism, leaving a residual and potentially
clinically significant enzymatic defect (28). Finally, evaluating
ADA2 activity after transplant, especially in case of mixed
chimerism, allows monitoring the efficacy and promptly detect
the disease recurrence (27). Further studies are needed to define
the appropriate timing of HSCT and as well as intensity of
conditioning regimen.
CONCLUDING REMARKS
Early diagnosis of DADA2 in cases presenting with hematological
manifestations, rather than classical vasculopathy, is crucial,
allowing the patients to undergo HSCT, if indicated, before the
arousal of more severe manifestations of the disease. Moreover,
physicians can adjust the transplant procedure based on the
features of the disease, in order to minimize complications and
create the most favorable conditions to allow an efficacious
control of the disease. Finally, this case highlights the importance
of reaching a genetic diagnosis before HSCT. If transplant
cannot be delayed, a related donor should be excluded in all
cases of genetic disease suspicion without precise molecular
diagnosis: an unrelated donor would give the possibility to
avoid relapse or partial benefit due to a common genetic
defect.
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